Peptide Therapy Research: Evidence Summaries, Mechanisms, and Regulatory Status for Widely Discussed Peptides
Peptide research occupies an unusual position. Two compounds in this field are among the most rigorously studied drugs of the past decade, supported by large randomized trials and cardiovascular outcome data. Most of the others are supported by rodent studies, a handful of small trials conducted decades ago in other countries, or nothing published at all. Both groups are discussed online in the same tone of voice, which is the problem this site exists to address.
Every compound covered here is graded on the same scale, and the grade reflects the strength of the human evidence rather than the volume of the discussion around it.
How We Grade the Strength of Human Evidence Behind Each Research Peptide
A low tier is not a verdict that a compound does nothing. It is a statement that the research needed to answer the question has not been done, which is a different and more honest claim.
Metabolism and Weight Loss Peptides: Incretin Agonists and Growth Hormone Fragments Compared
| Compound | Mechanism studied | Evidence tier |
|---|---|---|
| Tirzepatide Mounjaro, Zepbound | Dual GIP and GLP-1 receptor agonist affecting insulin secretion, gastric emptying, and appetite signaling | Tier 1. Approved for type 2 diabetes and chronic weight management, with the largest mean weight reductions reported in the incretin class |
| Semaglutide Ozempic, Wegovy, Rybelsus | GLP-1 receptor agonist; appetite suppression, delayed gastric emptying, glucose-dependent insulin release | Tier 1. Approved across multiple indications, with published cardiovascular outcome data |
| AOD-9604 | Fragment of human growth hormone, proposed to promote lipolysis without the glucose effects of full-length GH | Tier 3. Reached human obesity trials but did not demonstrate meaningful weight loss over placebo, and development for that indication was not carried forward |
The gap in this category is instructive. Tirzepatide and semaglutide are prescription medicines with mandatory labeling, adverse event reporting, and known risks including gastrointestinal effects and gallbladder events. AOD-9604 is frequently marketed alongside them as though it belongs in the same evidentiary conversation. It does not, and the reason is that it was tested in humans and the result was disappointing.
Healing, Injury Recovery, and Growth Hormone Secretagogue Peptides and What the Data Supports
| Compound | Mechanism studied | Evidence tier |
|---|---|---|
| BPC-157 | Pentadecapeptide derived from a gastric protein; rodent work reports angiogenic and tendon, ligament, and gut-lining repair effects | Tier 3. A large preclinical literature, overwhelmingly from animal models, with no published controlled human efficacy trials |
| TB-500 Thymosin beta-4 fragment | Actin-binding peptide studied for cell migration, angiogenesis, and inflammatory modulation in tissue repair | Tier 3. Preclinical repair data; full-length thymosin beta-4 has been trialed in humans for specific ophthalmic and wound indications, which is not the same compound or use |
| CJC-1295 with Ipamorelin | GHRH analog paired with a ghrelin receptor agonist to raise endogenous growth hormone pulses | Tier 3. The pharmacology is real and measurable, but raising GH and IGF-1 is a biomarker change, not a demonstrated clinical outcome |
| Sermorelin | GHRH analog corresponding to the first 29 amino acids of growth hormone-releasing hormone | Tier 2. Holds a distinct regulatory history from the compounds above, having previously been marketed in the United States before being withdrawn commercially |
BPC-157 illustrates a recurring pattern in this field. The animal literature is genuinely substantial, and researchers who work with it are not inventing their results. What has never happened is the step that matters for human use: a randomized, controlled, adequately powered trial in people. Enthusiasm has run ahead of that step by roughly a decade.
Cognitive, Nootropic, Sleep, and Skin Peptides Studied for Neurological and Dermatological Effects
| Compound | Mechanism studied | Evidence tier |
|---|---|---|
| Semax | Synthetic analog related to a fragment of ACTH, studied for neurotrophic and neuroprotective signaling including BDNF expression | Tier 2 to 3. Developed and used clinically in Russia, with limited independent replication in the Western peer-reviewed literature |
| Selank | Tuftsin-derived peptide investigated for anxiolytic effects without the sedation associated with benzodiazepines | Tier 2 to 3. Small clinical studies concentrated in one national research tradition, with sparse independent confirmation |
| DSIP Delta sleep-inducing peptide, emideltide | Identified in the 1970s in connection with sleep-related electrical activity; proposed effects on sleep architecture | Tier 4. Decades old, thinly replicated, and inconsistent; the weakest evidence base of any compound covered here |
| GHK-Cu | Copper-binding tripeptide studied for collagen synthesis, extracellular matrix remodeling, and wound repair signaling | Tier 2 topical, Tier 4 injectable. Cosmetic topical studies exist, generally small; the injectable route is a separate question with far less supporting data |
GHK-Cu is worth separating carefully by route. A topical cosmetic ingredient with small published studies behind it and an injectable preparation of the same molecule are different propositions with different risk profiles, and conflating them is common in marketing copy.
United States Regulatory Status in 2026: FDA Approval, Compounding Categories, and the July Advisory Vote
Semaglutide and tirzepatide are FDA-approved prescription medicines. None of the other compounds described on this page holds FDA approval for any human indication.
In 2023 the FDA placed roughly nineteen peptides, including BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, Semax, Selank, DSIP, and injectable GHK-Cu, into Category 2 of its bulk drug substances list, meaning they were flagged as presenting significant safety risks and could not be compounded by licensed pharmacies. In April 2026 a group of those substances was removed from Category 2, which reopened a review pathway rather than granting permission.
On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee reviewed seven nominated peptides and recommended six of them for the 503A bulks list by narrow margins, including BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. Emideltide, the delta sleep-inducing peptide, was the single rejection. The committee voted against the written recommendations of FDA career scientists, who had advised against all seven on the grounds of insufficient safety and effectiveness evidence.
Three points are routinely blurred together and should not be. A committee recommendation is advisory and not binding. Placement on the compounding list requires formal notice-and-comment rulemaking, which takes months at minimum. And compounding eligibility would still not make any of these compounds an FDA-approved drug.
Because this area is moving quickly, every regulatory statement on this site carries the date it was accurate. Readers checking a page months from now should assume the position may have changed and verify against current FDA publications.
Why Research-Grade Peptide Products Are Not Pharmaceutical Products and What That Distinction Means
Material sold for laboratory use is not manufactured, tested, or released under the standards applied to injectable medicines.
Independent testing of grey-market peptide products has repeatedly found content that differs from the label, including underdosing and contamination.
Free base, acetate, and TFA salt forms are often used interchangeably in marketing, a problem FDA reviewers themselves have flagged as obstructing evaluation.
Growth hormone secretagogues, GHRH analogs, and several repair peptides are prohibited in competitive sport at all times under anti-doping rules.
Editorial Approach: What This Site Publishes and What It Deliberately Does Not
We summarize mechanisms, describe study designs and their limitations, and record regulatory status with dates. We distinguish between a biomarker moving and a clinical outcome improving, because in this field those are constantly conflated. Where a compound’s supporting evidence comes from a single research group or a single country, we say so rather than presenting it as settled.
We do not publish dosing protocols, reconstitution or administration instructions, cycle designs, or vendor recommendations. Those belong in a clinical relationship with a licensed prescriber, and publishing them for unapproved injectable drugs would put readers at risk regardless of how the information were framed. We also do not accept payment from sellers of peptide products in exchange for coverage or favorable framing.
Content on this site is for informational and educational purposes and is not medical advice. It is not a recommendation to obtain or use any compound described here. Most of these substances are unapproved drugs, and self-administration of injectable unapproved drugs carries risks including infection, contamination, allergic and immune reactions, and unknown long-term effects.
Growth hormone secretagogues alter endocrine signaling and may affect glucose regulation and IGF-1 levels, which raises specific concerns for people with diabetes or a history of malignancy. Approved incretin medicines carry their own documented adverse effects and require prescriber supervision.
Anyone considering any therapy discussed here should consult a licensed physician who knows their medical history. In a medical emergency, call 911.
Mechanism summaries, evidence grading, and regulatory tracking for therapeutic peptides including tirzepatide, semaglutide, BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin, Semax, Selank, DSIP, AOD-9604, and GHK-Cu.